Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Levophed

(norephinephrine)

 

INDICATIONS:

 

  • Cardiogenic shock
  • Neurogenic shock
  • Septic shock
  • Anaphylactic shock

 

DOSAGE:

 

  • ADULT:
    • Gtt: 4 mg in 250 mL bag 2-30 mcg/min; max of 30 mcg/min IV/IO

 

PEDIATRIC:

 

  • Not Approved

 

 

CONTRAINDICATIONS:

 

  • Hypotension due to uncontrolled hemorrhagic shock
  • Vascular Thombosis
  • Profound hypoxia

 

SIDE EFFECTS:

 

  • Bradycardia
  • Anxiety
  • Shortness of Breath
  • Nausea/Vomiting